Todos Medical (OTCMKTS:TOMDF) versus PolyPid (NASDAQ:PYPD) Head-To-Head Survey

Todos Medical (OTCMKTS:TOMDF) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares Todos Medical and PolyPid”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Medical	$12.23 million	0.02	-$43.31 million	N/A	N/A
PolyPid	N/A	N/A	-$23.86 million	($12.64)	-0.26

PolyPid has lower revenue, but higher earnings than Todos Medical.

Volatility & Risk

Todos Medical has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Todos Medical and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Medical	N/A	N/A	N/A
PolyPid	N/A	-969.85%	-121.65%

Analyst Recommendations

This is a breakdown of recent recommendations for Todos Medical and PolyPid, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Medical	0	0	0	0	N/A
PolyPid	0	0	1	0	3.00

PolyPid has a consensus target price of $14.00, suggesting a potential upside of 324.24%. Given PolyPid’s higher possible upside, analysts clearly believe PolyPid is more favorable than Todos Medical.

Summary

PolyPid beats Todos Medical on 6 of the 9 factors compared between the two stocks.

About Todos Medical

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.